Welcome to our dedicated page for Lifevantage SEC filings (Ticker: LFVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LifeVantage Corporation filings document formal disclosures for a Nasdaq-listed health and wellness company that sells nutrigenomic supplements, skin and hair care products, energy drink mixes, and pet supplements through an independent Consultant model. Recent Form 8-K reports furnish quarterly operating results and describe revenue by region, earnings measures, capital allocation, and material corporate events.
Proxy and meeting filings cover board elections, advisory executive compensation votes, auditor ratification, incentive-plan matters, and final stockholder voting results. Other current reports address executive departures, officer appointments, board changes, transition agreements, and compensatory arrangements, alongside exhibit-based press releases tied to financial results and governance actions.
Lifevantage Corp (LFVN) reported a Form 4 showing equity awards to Julie Boyster, the company's Chief Marketing Officer. The filing discloses a non‑derivative grant of 13,102 common stock units on 08/26/2025, increasing her directly held common shares to 128,316. The filing also shows 19,654 Performance Restricted Stock Units (PRSUs) granted the same date, representing rights to receive that many shares if performance targets are met; the PRSUs count as 19,654 underlying shares for beneficial ownership. The stock units vest over time subject to continued service: 5/12 of the stock unit award vests on September 10, 2026, with the remainder in equal installments across seven calendar quarters thereafter. The PRSUs vest only to the extent financial performance criteria are achieved and, if earned, vest in three tranches on September 10, 2026, 2027 and 2028 (34%, 33%, 33%). The Form 4 was signed by a power of attorney on 08/28/2025.
Lifevantage Corp (LFVN) reporting person Steven R. Fife, President and CEO and a director, received non‑derivative and derivative equity awards on 08/26/2025. He was granted 48,193 stock units that represent rights to receive common stock and will hold 659,500 shares beneficially following the grant. He also received 72,289 Performance Restricted Stock Units (PRSUs) at target, with each PRSU representing one share at $0 exercise price; PRSU vesting is contingent on performance and continued service.
The stock units vest partly on September 10, 2026 and then in installments across seven quarters; PRSU vesting, if earned, vests 34% on September 10, 2026, 33% on September 10, 2027 and 33% on September 10, 2028. The Form 4 was signed by a power of attorney on 08/28/2025.
Lifevantage Corp (LFVN) reporting person Kristen Cunningham, Chief Sales Officer, received equity awards on 08/26/2025. The filing shows a grant of 12,349 stock units (each convertible to one share) and 18,524 performance restricted stock units (PRSUs) representing target-level awards. Following the transactions, Cunningham beneficially owns 116,351 shares and 18,524 PRSU-equivalent shares reported as direct ownership. The stock units vest over time subject to continued service, and the PRSUs vest only if specified performance criteria are met, with potential payout up to 200% of target.
Lifevantage Corp (LFVN) Chief Financial Officer Carl Aure received equity awards on 08/26/2025. The Form 4 reports an award of 10,241 stock units that represent rights to receive common shares and 15,361 Performance Restricted Stock Units (PRSUs) that are earned based on specified financial performance criteria. After the reported transactions, the filing shows 143,544 shares beneficially owned and 15,361 derivative shares from PRSUs. The stock units vest over time with a schedule beginning September 10, 2026, and the PRSUs vest contingent on performance and continued service with vesting dates in 2026–2028. The form was signed by power of attorney on 08/28/2025.